Overview

A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients. Gimatecan is administered orally twice per week, every 28 days, to adult patients with advanced solid tumors who have progressed despite standard therapy or for whom standard systemic therapy dose not exist.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis

Treatments:

Camptothecin